Evofem Biosciences Inc (EVFM) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health. Its commercial product, Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel (Phexxi), is a hormone-free and woman-controlled prescription contraceptive drug product available in the United States. Its lead clinical program is evaluating EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. Its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), EVO200 vaginal gel, uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
Contact details
Important dates
General stock information
- Short code:
- EVFM
- ISIN:
- US30048L3024
- Market cap:
- $278,990
- Shares in issue:
- 10.73 million
- Sector:
- Pharmaceuticals
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.